291 related articles for article (PubMed ID: 19877382)
1. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
[TBL] [Abstract][Full Text] [Related]
3. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
5. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
8. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
9. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
11. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
12. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
14. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
[TBL] [Abstract][Full Text] [Related]
15. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
17. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
18. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
[TBL] [Abstract][Full Text] [Related]
19. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
[TBL] [Abstract][Full Text] [Related]
20. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
